BIODESIX, INC. Deferred Revenue Recognized
BIODESIX, INC. (BDSX) reported Deferred Revenue Recognized of $300.00 thousand for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-07.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2024-08-07
- BIODESIX, INC. contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was $200.00K, a 0.00% change year-over-year.
- BIODESIX, INC. contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was $200.00K, a 33.33% decline year-over-year.
- BIODESIX, INC. contract with customer, liability, revenue recognized for the quarter ending 2022-03-31 was $300.00K.
- BIODESIX, INC. contract with customer, liability, revenue recognized for fiscal 2023 was $1.30M.
- BIODESIX, INC. contract with customer, liability, revenue recognized for fiscal 2021 was $1.20M, a 60.00% decline from fiscal 2020.
- BIODESIX, INC. contract with customer, liability, revenue recognized for fiscal 2020 was $3.00M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month | Contract with Customer, Liability, Revenue Recognized 12 month as first filed |
|---|---|---|---|---|---|
| 2024-06-30 | $300.00K 10-Q · filed 2024-08-07 | ||||
| 2024-03-31 | $200.00K 10-Q · filed 2024-05-08 | ||||
| 2023-12-31 | $1.30M 10-K · filed 2024-03-01 | ||||
| 2023-09-30 | $900.00K 10-Q · filed 2023-11-07 | ||||
| 2023-06-30 | $400.00K 10-Q · filed 2023-08-07 | ||||
| 2023-03-31 | $200.00K 10-Q · filed 2023-05-11 | ||||
| 2022-09-30 | $1.40M 10-Q · filed 2022-11-03 | ||||
| 2022-06-30 | $800.00K 10-Q · filed 2022-08-04 | ||||
| 2022-03-31 | $300.00K 10-Q · filed 2022-05-11 | ||||
| 2021-12-31 | $1.20M 10-K · filed 2023-03-06 | ||||
| 2020-12-31 | $3.00M 10-K · filed 2022-03-14 | $700.00K 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |